MedPath
NMPA Approval

Lamivudine and Dolutegravir Sodium Tablets

国药准字HJ20210013

March 2, 2021

Drug Information

拉米夫定多替拉韦片

多伟托

片剂

每片含拉米夫定300mg和多替拉韦钠(以多替拉韦计)50mg

化学药品

March 2, 2021

March 1, 2026

Company Information

Applicant Company

ViiV Healthcare BV

Van Asch van Wijckstraat 55H, 3811 LP Amersfoort, Netherlands

Manufacturing Company

glaxosmithkline llc;glaxo wellcome s.a.

1011 North Arendell Avenue, Zebulon, 27597, North Carolina, USA;Avenida Extremadura No. 3, Aranda De Duero (Burgos), 09400 Spain

© Copyright 2025. All Rights Reserved by MedPath